Infliximab for refractory ulcerative colitis |
| |
Authors: | Chey W Y Hussain A Ryan C Potter G D Shah A |
| |
Affiliation: | Konar Center for Digestive and Liver Diseases, Rochester, New York, USA. |
| |
Abstract: | Eight patients with active ulcerative colitis (UC), refractory to usual combination medical therapy, were treated with a single i.v. dose of chimeric monoclonal antibody to recombinant human tumor necrosis factor alpha; many of these patients were scheduled for surgical colectomy because of their active disease. All patients responded extremely well to a single 5 mg/kg infusion of infliximab, with marked improvement after the infusion clinically, colonoscopically, and histologically on colonic biopsy. There were no significant complications or side effects; mean duration of remission has not been determined because none of the patients have relapsed. Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|